Skip to main content

PTD-DBM

No sources yet

An index of captured practitioner sources, not a completed evidence summary. Unchecked figures and empty sections are omitted. See the library review status.

Source summary generated November 6, 2026; this date does not indicate completed review.

Tissue researchAliases: CXXC5-Dishevelled blocker
Track your own protocol free →

Quotes from three independent practitioners, with their sources. Research context only.

What it is and how it works

From the published literature on PTD-DBM; the papers are listed at the end. Research summary, not a recommendation.

What it is

PTD-DBM is an experimental peptide made by fusing a protein transduction domain (a short sequence that carries molecules into cells) to a Dishevelled-binding motif (a stretch copied from the CXXC5 protein). It was developed by Kang-Yell Choi's group at Yonsei University and published in 2017 as a competing peptide that blocks the interaction between CXXC5 and the protein Dishevelled. All published work found is in cells and mice; no human trial of PTD-DBM was found in PubMed as of 2026-11-06.

How it works

The Wnt/beta-catenin pathway (a cell-signaling route that drives hair follicle development and regrowth) is switched down by CXXC5, which attaches to Dishevelled, a relay protein in the pathway. CXXC5 was found at higher levels in miniaturized hair follicles of balding human scalp. By competing with CXXC5 for Dishevelled, PTD-DBM released the pathway, accelerating hair regrowth and the formation of new hair follicles after wounding in mice. A later study found it also reversed hair loss caused by prostaglandin D2, a substance linked to androgen-driven hair loss, in mice.

What it has been studied for

  • Hair regrowth in mice (animal study)
  • Wound-induced new hair follicle formation in mice (animal study)
  • Hair loss driven by prostaglandin D2 and the hormone DHT in a mouse model (animal study)

Strength of the evidence

Animal and lab studiesPublished data are cell and mouse studies from one research network; no human trial was found.

What the literature reports on safety

No safety data in people were found. A 2025 review of Wnt-pathway hair therapies said such treatments need further research to validate efficacy and risk profile. PTD-DBM is not an approved drug and is not named on the FDA compounding-substances page (content current as of 2026-04-22).

Key papers

  1. Targeting of CXXC5 by a Competing Peptide Stimulates Hair Regrowth and Wound-Induced Hair Neogenesis. (opens in a new tab)

    Animal study · Lee SH, Seo SH, et al. · Journal of Investigative Dermatology (2017) · PMID 28595998

    CXXC5 was raised in balding human scalp, mice lacking it regrew hair faster, and a competing peptide that blocked CXXC5 binding to Dishevelled accelerated regrowth and new follicle formation.

  2. CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD2. (opens in a new tab)

    Animal study · Ryu YC, Park J, et al. · Cells (2023) · PMID 36831222

    Hair loss caused by prostaglandin D2 was reversed in mice by PTD-DBM or by deleting Cxxc5, and DHT-induced hair loss was eased by blocking CXXC5 and GSK-3 beta.

  3. The Negative Regulator CXXC5: Making WNT Look a Little Less Dishevelled. (opens in a new tab)

    Review · Kim D, Garza LA · Journal of Investigative Dermatology (2017) · PMID 28967390

    An accompanying commentary on the 2017 study describing CXXC5 as a negative regulator of Wnt signaling in hair follicle regeneration.

  4. KY19382, a novel activator of Wnt/beta-catenin signalling, promotes hair regrowth and hair follicle neogenesis. (opens in a new tab)

    Animal study · Ryu YC, Lee DH, et al. · British Journal of Pharmacology (2021) · PMID 33751552

    A small molecule that blocks the same CXXC5-Dishevelled interaction was tested in human dermal papilla cells, cultured human follicles and mice, extending the target to a non-peptide compound.

  5. Revolutionary Approaches to Hair Regrowth: Follicle Neogenesis, Wnt/beta-Catenin Signaling, and Emerging Therapies. (opens in a new tab)

    Review · Mehta A, Motavaf M, et al. · Cells (2025) · PMID 40497955

    Reviewed Wnt-pathway hair therapies including PTD-DBM and concluded they need further research to validate efficacy and risk.

Sources checked: PubMed (E-utilities abstracts for every PMID), FDA compounding-substances page (current as of 2026-04-22), written 2026-11-06.

No sources yet

None of the three teachers' sources we have indexed discuss PTD-DBM yet. This page will fill in as sources are added.

Deeper guided audio lives on What Am I Appreciating Now (leaves this site, opens in a new tab). What Am I Appreciating Now is a separate site run by the same operator; it sells meditation and hypnosis sessions.

Disclaimer: for research purposes only

All content on this page is for research and educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any peptide or hormone protocol. You take responsibility for your own protocol.If your path includes peptides, you buy them yourself from an independent licensed provider through a member co-op; we take nothing. How independent access works.

PTD-DBM — Hunter, Taylor, Bachmeyer | Reset Biology